Redx Pharma Plc is a biotech company listed on AIM that specializes in discovering and developing targeted medicines to fight cancer and fibrotic disease. Its team of 50 scientists is located at Alderley Park, Cheshire, the UK's leading life science campus, and is comprised of experts in medicinal chemistry, biology, and clinical development. The company's main focus is its lead oncology asset, RXC004, which is currently undergoing a phase 1 clinical trial for patients with advanced malignancies. RXC007, the company's ROCK2 selective inhibitor, is anticipated to enter clinical trials next year. The team has significant experience in biotech and large pharma, lending it a strong foundation in the industry.
Redx Pharma Plc's ticker is REDX
The company's shares trade on the LSE stock exchange
They are based in Macclesfield, England
There are 11-50 employees working at Redx Pharma Plc
It is https://www.redxpharma.com/
Redx Pharma Plc is in the Healthcare sector
Redx Pharma Plc is in the Biotechnology industry
The following five companies are Redx Pharma Plc's industry peers: